5 Crescent Drive
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2852 articles with GlaxoSmithKline
Desperate For A Do-Over? New "Take Two" Campaign By Excedrin® Offers Migraine Sufferers A Second Chance To Re-Live Milestone Moments Marred By Migraines
Nearly nine out of 10 migraine sufferers say they've missed important life events and special moments with friends and family due to a migraine, making fear of missing out an everyday reality for the more than 39 million migraine sufferers in the United States1.
It was another busy week for clinical trials. Here’s a look.
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults.
Thermo Fisher Scientific Inc., the world leader in serving science, has completed its previously announced acquisition of an active pharmaceutical ingredient manufacturing facility from GlaxoSmithKline for €90 million.
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
GlaxoSmithKline plc announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
9/27/2019Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
9/26/2019Companies from across the globe share updates on their business and pipelines.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
Research from the Wellcome Sanger Institute, GSK and Biogen, under the Open Targets initiative, has shown that thousands of differences in DNA between individuals, associated with immune diseases, are linked with the switching-on of a specific subtype of immune cells.
Immutep Limited announces that it will receive a milestone payment from GSK of GBP 4 million related to the the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
Immutep Limited announces that it will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
9/23/2019Microsoft announced that Emma Walmsley, chief executive officer of GlaxoSmithKline, had been nominated to the company’s board of directors.
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the United States, the company said.
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
GlaxoSmithKline announced that the US Food and Drug Administration has approved Nucala for use in children as young as six years old who are living with severe eosinophilic asthma.
GSK to obtain transglutaminase 2 small molecule program for celiac disease